Monday - Friday - 7:30am - 6:00pm   /   Lunes - Viernes - 7:30am - 6:00pm

Welcome

Fundación de Investigación (FDI) is a first rate research site with state-of-the-art facilities and medical care clinics with access to a viable patient population for research trials. We have a database of normal volunteers and the capability to conduct clinical trials at all stages of drug development, from First-in-Man, Proof of Concept (POC), to Phase 1 to Phase 3 studies. We also conduct selected post-approval or post-marketing Phase 4 studies, when there is interest in obtaining additional information, or to analyze the efficacy and safety of a particular drug in special populations. We have conducted hundredths of clinical trials in multiple therapeutic areas: Infectious Diseases as hepatitis C, hepatitis B, Influenza, and Herpes Zoster; Hematology and Oncology, all types of Cancers including Acute and Chronic Leukemia; Vaccines; Metabolic Syndrome manifestations as Diabetes Mellitus, Arterial Hypertension, Non alcoholic steatohepatitis (NASH) and Obesity; Rheumatology and Immune Diseases as Rheumatoid Arthritis, Systemic Erythematous Lupus, Osteoarthritis and Gout; Respiratory Diseases as Asthma, Chronic Obstructive Pulmonary Disease and others. Our site's advanced technology includes a phase I unit and an in-house bio-analytical laboratory.

 

Our 30-bedPhase I Unitis the only one in the Caribbean and one of the few in South America. Our Phase I unit has state-of-the-art monitoring technology that includes remote telemetry and sophisticated software designed to manage phase I trials. Our phase I unit’s experienced staff and facilities allow the trials to be conducted without interruption 7 days a week. 

Phase 1 Unit From recruitment through final reporting, we use;

  • Logos Technologies’ ALPHADAS EDC software,
  • Mortara 12-lead wireless telemetry instruments and
    Surveyor™ Telemetry Central system
  • WebDMEMR as our electronic medical record provider.

Fundación Bioanalytical Laboratory (FBL)is a unit of Fundación de Investigación de Puerto Rico that specialize in qualitative and quantitative analysis of chemical and biological pharmaceutical compounds. We provide added value to our customers by advising on the scientific and regulatory situations that could arise in the development of these compounds.

 

We are a one-stop facility where customers can perform Phase 1 and Phase 2 studies in the same facilities including pharmacokinetics and pharmacodynamics assessments. This strategy provides faster results for companies’ decision making process for the development of their products. FDI has conducted trials with confinement duration of up to 16 days, including multiple intensive pharmacokinetics and pharmacodynamics trials as SAD and MAD for many molecules. We also conduct hepatic impairment and drug-to-drug interaction studies. We provide to our customers not only scientific but also clinical expertise in the development of pharmaceutical products. Our scientists have extensive experience in the development and validation of bioanalytical methods in the determination of small molecules and their metabolites.

 

In addition, our investigators frequently submit research proposals to Government and Pharmaceutical Companies to be conducted as Investigator Initiated Studies (IIS), and we participate in collaborations conducting basic research and also joint ventures to develop drugs in Puerto Rico from local and external biomedical companies. For 2015, we will be conducting in-hospital clinical trials in other populations, like serious infections, pediatrics and emergency medicine.

 

FDI evaluates all offers and opportunities to conduct clinical trials and works with the sponsors to conduct the studies efficiently, quickly and at the most competitive costs. We also welcome any opportunity to partner in drug development. Our reputation as a top clinical trial enroller, our emphasis on quality, plus our extensive experience in research and development, make us the best choice for your clinical trial. We deliver results for you, faster and better.

 

For more information or questions, please contact our  Director of Clinical Research Operations, Ms. Michelle Echeandia (This email address is being protected from spambots. You need JavaScript enabled to view it.) or 1-787-722-1248.

 

 

Logos Tech Mortara WebDMEMR

 

Who We Are?

Located in San Juan, Puerto Rico, Fundación de Investigación (FDI) is a clinical research center with state-of-the-art facilities that comprise medical treatment for multiple conditions, a 30-bed phase I unit, an in-house bioanalytical laboratory, multispecialty experienced personnel, and the latest in medical technology. We are also an active medical care facility for patients with diverse medical ailments.

Executive Leadership

Dr. Jose F. Rodriguez-Orengo
Chief Executive Offcicer - CEO,
Chief Scientific Officer & BioLab Director


Grisell Ortíz-Lasanta, MD
Associate Director

Mirelis Acosta, MD
Chief Medical Officer

Michelle Echeandia
Chief Operating Officer

Our partners

Gilead Pharmaceuticals
Amgen
Astra Zeneca
Bristol Myers Squibb
GlaxoSmithKline
Merck Sharp
Novartis Pharmaceuticals
Pfizer
Sanofi-aventis
Jansen Pharmaceuticals

Where to find us?

Address
Fundación de Investigación
998 Muñoz Rivera Ave.
San Juan, PR 00927

Phone Number
Tel. (787) 722-1248
Fax. (787) 721-6098